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ABSTRACT 
 
 
OBJECTIVE: The objective of this selective EBM review is to determine “Does Metformin use 
during pregnancy effectively reduce the rate of early pregnancy loss in women with polycystic ovary 
syndrome?” 
 
STUDY DESIGN: This review is based on two primary double-blind, randomized controlled trials and 
a prospective controlled trial that was not randomized or blinded to evaluate whether metformin, a 
medication used to manage PCOS, can also prevent early pregnancy loss in women with PCOS.  
 
DATA SOURCES: All articles used were published in English, in peer-reviewed journals, and located 
through PubMed, OVID and COCHRANE databases.. 
 
OUTCOMES MEASURED: Each of the three trials included evaluated the effectiveness of 
metformin at preventing pregnancy loss and premature labor in patients with PCOS, as well as safety of 
administering the drug during pregnancy. Sohrabvand et al solely focused on early pregnancy loss, with 
other studies following pregnancy to term.  
 
RESULTS: Two double-blind randomized controlled trials and one prospective controlled trial were 
included in this review. Results from the Vanky et al (2004) study demonstrated a 22.7% decrease in 
premature birth rate in metformin group as compared to control. Sohrabvand et al also presented a 
statistically significant decrease in current miscarriage rate in groups taking metformin up to 8 weeks 
and 12 weeks, of gestation (p = 0.008 and p = 0.002, respectively) as compared to previous miscarriage 
rate. Vanky et al (2010) analyzed a multicenter trial, but its results differed in that a statistically 
significant decrease in preterm labor could only be appreciated after a subgroup analysis was 
performed of participants deemed to have good and acceptable compliance (7.4% decrease, p = 0.03). 
The recommendation made in this last trial was not in favor of metformin usage due to a perceived 
overall lack of benefit.    
 
CONCLUSIONS: Two of the three trials in this review support the use of metformin during 
pregnancy in women with PCOS as means of preventing pregnancy loss or premature labor. Various 
factors, such as tighter monitoring throughout pregnancy, and inconsistencies in pre-pregnancy 
metformin intake could have affected the results within this patient population.  
 
KEY WORDS: polycystic ovary syndrome, miscarriage, pregnancy 
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INTRODUCTION 
 
 Polycystic ovary syndrome (PCOS) is otherwise known as Stein Leventhal Syndrome. It carries 
no specific predilection for race or ethnicity, and is a multifactorial disorder characterized by 
anovulation, polycystic ovaries, insulin resistance, and hyperandrogenism.1 It can result in numerous 
complications, and one of them, early pregnancy loss, is the focus of this paper.2 This paper is primarily 
based on two double-blind, randomized controlled trials and a prospective controlled trial that was not 
randomized or blinded to evaluate whether metformin, a medication used to manage PCOS, can also 
prevent early pregnancy loss  in women with PCOS.  
 PCOS and its related complications are relevant to the Physician Assistant practicing today due 
to the vast proportion of female patients plagued by the disorder. Based on data from 2003-2008, the 
number of PCOS-related doctor office visits reached an astounding total of 2,328,000 visits, with a 
mean yearly number of 516,000 visits.3 Because of these factors, PCOS has also proved to be quite an 
expensive condition to manage. The most recent data regarding cost of PCOS-related complaints spans 
the period between 2003-2008, and demonstrated a total cost of $1.16 billion annually.3 Overall, PCOS 
affects 5-10% of the female population in the US, a pretty significant percentage, especially when its 
consequences and related disorders are considered: diabetes mellitus, infertility, metabolic syndrome, 
and cardiovascular disease. Early pregnancy loss is the focus in this paper, and is also a frustrating 
aspect of PCOS, as becoming pregnant alone can prove to be quite a challenge.1  
 The exact cause of PCOS is unknown, but it has been attributed to a pattern of genetic 
inheritance, as it tends to be seen more frequently among relatives.1 The role of PCOS in leading to 
infertility, as well as early pregnancy loss, is multifactorial and is strongly believed to be caused by the 
combination of hyperandrogenism, alterations in gonadotropin secretion, and the insulin resistance, 
among other things.4   
 In treatment of PCOS, initially a trial of diet and exercise aimed at weight loss is recommended, 
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as women with PCOS are typically overweight. Often, achieving a healthy weight is enough to relieve 
some of the symptoms associated with the disorder. If poorly controlled by diet and exercise, insulin 
resistance is managed with metformin, and frequently has favorable outcomes in restoring ovulation as 
well.1 If additional help is needed for stimulation of ovulation, clomiphene citrate can be used.1 
Management of potential cardiovascular and metabolic syndrome complications is addressed as well in 
the form of pushing for weight loss, and supplementing with pharmacotherapy as deemed appropriate.1  
 Often, the above mentioned treatments are enough to adequately manage the disorder. However, 
it is widely known that even with appropriate management, women with PCOS often have a very hard 
time achieving a pregnancy. As if that were not enough, maintaining that pregnancy can additionally 
prove to be futile, as early pregnancy loss is quite common in these patients.5 Numerous interventions 
have been looked at as a potential 'remedy' for prevention of this complication, but not many have 
shown success. The studies evaluated in this paper demonstrate that metformin, a drug given to manage 
anovulation and hyperinsilunemia in PCOS, can be continued after the patient becomes pregnant and 
has actually shown a positive outcome related to maintenance of the pregnancy.5   
OBJECTIVE 
 The objective of this selective EBM review is to determine “Does Metformin use during 
pregnancy effectively reduce the rate of early pregnancy loss in women with polycystic ovary 
syndrome?” 
METHODS 
 The studies that were used to answer this question all fit the following criteria: the populations 
studied consisted of women of reproductive age, 18-45 years old, and diagnosed with PCOS, who also 
had a confirmed viable pregnancy. The intervention used was a dose range of Metformin 500-850mg 
given three times a day to the treatment group. The comparison group in the studies received a visually 
matched placebo. Additionally, previous history of miscarriages in these women was used for 
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comparison with the outcomes after the trial with metformin. Outcomes that were measured surrounded 
the efficacy of metformin in helping to maintain a viable pregnancy past the first trimester without 
complications or pregnancy loss. Types of studies used in this systematic review included two double-
blind, randomized controlled trials and a prospective controlled trial that was not randomized or 
blinded.  
 Key words that were used in searching for appropriate studies included metformin, pregnancy 
and PCOS. All articles used were published in English, in peer-reviewed journals, and located through 
PubMed, OVID and COCHRANE databases. The articles/studies were researched by the author, and 
selected based on the type of trial conducted, focus on patient-oriented outcomes (POEMs), and of 
course their direct relevance to the clinical question presented. Inclusion criteria for the systematic 
review included randomized, controlled, double-blind studies, as well as controlled trials that were not 
randomized, included POEMs, and had a publish date after 1996. Exclusion criteria included studies 
that were comparing metformin with other drugs in prevention of pregnancy loss in PCOS, or using 
metformin in combo with another drug. Reluctance to take drugs during pregnancy, known alcohol 
abuse, previous diagnosis of diabetes mellitus, and treatment with oral glucocorticoids or other drugs 
known to interfere with metformin were exclusion criteria for the subjects recruited for the studies. 
Summary of statistics that were reported or used were relative risk reduction (RRR), absolute risk 
reduction (ARR), number needed to treat (NNT), confidence intervals, and p-values.  
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Demographics and characteristics of the studies utilized for this review are displayed in Table 1.  
 
Table 1. Demographics and characteristics of included studies 
Study  Type # Pts Age Inclusion Criteria Exclusion Criteria  W/D Interventions 
Vanky6, 2004 Double 
blind, 
placebo 
controlled 
RCT 
40 28-33 Diagnosis of PCOS 
before the actual 
pregnancy; Age 18-
40 years old; 
Gestational age 
between 5 and 12 
weeks 
Liver disease; 
Creatinine >130mmol/l 
Known alcohol abuse; 
History of diabetes 
mellitus; Fasting 
plasma glucose >5.6 
mmol/l; Treatment 
with oral 
glucocorticoids or use 
of drugs known to 
interfere with 
metformin 
 
2 Randomized to 
receive metformin 
(850mg) or visually 
matched placebo 
BID initiated with 
diagnosis of 
pregnancy and 
continued throughout 
gestation 
Vanky5, 2010 Double 
blind, 
placebo 
controlled 
multicenter 
RCT 
257 18-42 PCOS diagnosed 
according to the 
Rotterdam criteria; 
Age 18-45 yrs; 
Gestational age 
between 5 and 12 
weeks; 
A singleton viable 
fetus shown on 
ultrasonography 
Alanine 
aminotransferase 
higher than 90 IU/liter; 
Serum creatinine 
concentration higher 
than 1.70 mg/dl; 
Known alcohol abuse; 
Previously diagnosed 
diabetes mellitus or 
fasting serum glucose 
higher than 126 mg/dl 
at the time point of 
inclusion; Treatment 
with oral 
glucocorticoids, or use 
of drugs known to 
interfere with 
metformin 
12 Randomized to 
receive metformin 
(500 mg) or visually 
matched placebo 
BID 
Sohrabvand7, 
2009 
RCT 75 22-33 Pregnant women with 
history of infertility 
that was solely due to 
PCOS, based on 
Rotterdam 
criteria and 
confirmed by 
physician; Received 
metformin along with 
other ovulation-
inducing drugs prior 
to pregnancy 
Reluctance to take 
drugs during 
pregnancy 
0 Randomized to 
receive metformin  
(500mg TID) until 5-
6 weeks gestation in 
in Group A, 8 weeks 
gestation in Group B, 
and until 12 weeks of 
gestation in Group 
C., after which it was 
entirely 
discontinued.  
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OUTCOMES MEASURED 
 
 Of the various outcomes assessed in these trials, the ability of maintaining a pregnancy past the 
first trimester in women with PCOS taking metformin, as well as adverse reactions associated with 
taking the drug were the main point of focus. All outcomes were based on patient-oriented evidence 
that mattered (POEMs). Vanky et al (2004) initially compared the incidence of pregnancy 
complications in women with PCOS who were taking metformin with those who took an identically 
matched placebo, including premature delivery, gestational diabetes mellitus (GDM) and thrombotic 
events.6  Sohrabvand et al compared the occurrence of miscarriage among three separate groups of 
participants which either discontinued metformin after diagnosis of pregnancy, continued taking it until 
week 8 of gestation, or week 12 of gestation.7 The study additionally compared previous history of 
miscarriage in the participants with its occurrence during the trial. Vanky et al (2010) compared 
metformin and placebo groups in terms of the occurrence of premature delivery or miscarriage, 
preeclampsia, new GDM, and other complications of pregnancy.5    
RESULTS  
 
 Among all trials used in this review, dichotomous data was used to assess the outcomes 
measured. In the first trial by Vanky et al (2004) it was discovered that the only cases of pre-term 
delivery occurred within the placebo group, with no cases of miscarriages or preterm delivery 
occurring within the metformin group.6 (Table 2) Table 2 also demonstrates that there was no statistical 
difference among the patient characteristics in the two groups, including their previous history of 
miscarriage. Whereas no p-value was provided for this significant finding, the RRR was calculated to 
be 100%, ARR was 22%, and NNT was 5 patients (Table 3). This NNT suggests that for every 5 
patients treated with 850mg of Metformin once daily for first week and twice daily for all subsequent 
weeks of pregnancy, preterm delivery would be prevented in one additional woman with PCOS, than 
when treated with placebo. This study additionally suggested that metformin is safe in pregnancy, as it 
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did not appear to contribute to any severe pregnancy complications. A statistically significant p-value 
of 0.01 supports this conclusion, as 32% of women within the control group suffered severe pregnancy 
or post-partum complications, with complete absence of these complications in the metformin group.6 
There were 2 drop-outs from this trial, one due to inconvenient traveling distance, and the other due to 
motivation failure; none withdrew due to complications or intolerance of metformin.6   
Table 2. Selected patient characteristics at inclusion and results of trial 6   
 Metformin Placebo P 
# of Participants 18 22 –  
# of Former Pregnancies (%) 11 (61) 11 (50) 0.8 
# of Former Pregnancy Losses (%) 7 (39) 10 (54) 0.5 
Metformin Treatment at Conception (%) 8 (44) 11 (50) 0.7 
Gestational age at birth in days (SD) 282 (8) 266 (36) 0.06 
# of Pre-term deliveries (%) 0 (0) 5 (23) – 
 
Table 3. Analysis of efficacy of Metformin in prevention of preterm labor in PCOS 
 Relative risk reduction 
(RRR) 
Absolute risk reduction 
(ARR) 
Number needed to treat 
(NNT) 
Vanky6, 2004 100% 1/.22  4.54 = 5 patients  
 
 Sohrabvand et al stratified its participants into three groups based on the clinic in which they 
were initially interviewed.6 There were 25 participants within each group, and none dropped out. 
Conception within this patient population was assisted with a regimen of clomiphene citrate and 
1500mg metformin daily. Aside from comparison of the trial outcomes of each group, previous history 
of miscarriage was additionally compared with miscarriage occurrences during the trial. Within Group 
A, among participants who discontinued the metformin upon diagnosis of pregnancy, there was 1 
miscarriage compared with 6 former pregnancy losses, demonstrating a statistically insignificant p-
value of 0.06. Group B was administered metformin until the 8th week of gestation, and resulted in 1 
miscarriage compared with a history of 8 total pregnancy losses among the group. Group C continued 
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taking metformin until week 12 of gestation, and resulted in 2 miscarriages compared with a history of 
10 total miscarriages. The p-values for both Group B and C were statistically significant at 0.008 and 
0.002, respectively(Table 4).  These findings demonstrated the efficacy of metformin on two separate 
levels, as it appears to have reduced miscarriage history within the individual groups, as well as within 
the groups that continued taking metformin after the diagnosis of pregnancy.7       
Table 4. Patient Characteristics at Inclusion and Results of Trial7   
 Group 1 Group 2 Group 3 P value 
# of Participants 25 25 25  –  
Age (SD) 27.96 (5.7) 28.72 (3.57) 26.8 (3.88) 0.115 
Results Group 1 Group 2 Group 3 
# of Former Pregnancy Losses (%) 6 (20) 8 (32) 10 (40%) 
# of Current Miscarriage (%) 1 (4) 1 (4) 2 (8) 
P value 0.06 0.008 0.002 
 
 Vanky et al (2010), a randomized controlled multicenter study, initially recruited 364 
participants for its trial, however, 32 were excluded due to inability to meet inclusion criteria, and 58 
did not desire participation. Following randomization, a single participant from the experimental group 
was additionally excluded due to a 21-hydroxylase deficiency diagnosis.5  Within the placebo group 3 
patients were lost to follow-up due to miscarriages, resulting in a total of 135 participants within each 
arm of the trial. Primary endpoints of this trial included preterm delivery, and demonstrated a reduction 
of preterm delivery rate from 8.2% within the placebo group to 3.7% within the experimental arm, a 
finding that was determined to be not statistically significant (p = 0.12) (Table 5). However, of the 270 
participants within the study, 80.2%, or 216 women, were determined to have good and acceptable 
compliance, resulting in performance of a per protocol analysis.5  The analysis showed a statistically 
significant (p = 0.03) decrease in preterm birth occurrence among the two groups, demonstrating a 
7.4% decrease (CI=0.9–1.2), as compared with the previous 4.5% (CI=-10.1–1.2 ). RRR was calculated 
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to be 73%, ARR was 7.4%, and NNT was 14 patients, indicating that 14 pregnant women with PCOS 
would have to be treated with metformin to successfully prevent preterm labor in one additional 
woman (Table 6). No differences could be appreciated between the two groups in terms of 
preeclampsia and GDM in either the primary endpoints or the per protocol subgroup analysis, as 
demonstrated by p-values that were all statistically insignificant.5   
Table 5.  
Preterm Delivery / Miscarriage 
Occurrence 
Metformin (%) Placebo (%) 95% CI P value 
Primary endpoints 5/135 (3.7) 11/135 (8.2) -10.1–1.2 0.12 
Subgroup analysis 3/108 (2.8) 11/108 (10.2) 0.9–13.9 0.03 
 
Table 6. Analysis of efficacy of Metformin in prevention of preterm labor in PCOS 
 Relative risk reduction 
(RRR) 
Absolute risk reduction 
(ARR) 
Number needed to treat 
(NNT) 
Vanky6, 2010 73% 1/.074 13.5 = 14 patients  
 
DISCUSSION 
 
 Metformin is a drug belonging to the biguanide class, and is most widely known as the 
antidiabetic drug used in management of Type 2 diabetes mellitus. It was initially created to help 
control blood glucose levels in diabetics, however its use today spans across a spectrum of disorders 
involving insulin resistance.8 Metformin's mechanism of action mainly involves decreasing hepatic 
glucose production, however it also increases insulin sensitivity and glucose metabolism within certain 
organs and tissues, such as muscle, liver, and intestine. Within the intestine this metabolism results in a 
byproduct, lactate, which is typically taken up by the liver and used in the process of hepatic 
gluconeogenesis.  The exact molecular mode of action of metformin is not certain, but known to 
involve the enzyme AMP-activated protein kinase (AMPK), Peutz-Jeghers protein, and LKB1.  In 
addition to those mechanisms, metformin is also known to promote lowering of lipid levels and aiding 
in weight loss and management. Its action at decreasing blood glucose levels, managing insulin 
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resistance, and also decreasing androgen levels is believed to be the key in helping to manage PCOS-
related complications such as anovulation and infertility5 ,7.    
 Perhaps the most common side effects of metformin are gastrointestinal in nature, and include 
abdominal discomfort, nausea, possible vomiting, diarrhea, and a metallic taste in the mouth8. Vanky et 
al (2010) mentioned diarrhea and bloating as being more prevalent within the metformin group, with 
abdominal discomfort and nausea being equally prevalent5 . Vanky et al (2004) also mentioned nausea 
and abdominal discomfort as being equally prevalent among the two groups, however no participants 
dropped out of the study due to the side effects, and were instead told to take half the original dose of 
metformin5 .  
 Another side effect of metformin is lactic acidosis, and although it may mimic the 
gastrointestinal side effects, it is much more serious8. Symptoms include abdominal pain, nausea, 
vomiting, hypotension, and hyperventilation8. Metformin contributes to this condition in two ways: by 
increasing lactate production in the intestine, as previously mentioned, and by decreasing hepatic 
uptake of lactate8. This complication, however, is more associated with metformin overdose, kidney, 
lung, and liver disease, and wasn't present in any of the trials included in this review8..  
 Sohrabvand et al study was perhaps the only one in this review to directly address the effect of 
metformin on early pregnancy loss, as both of the Vanky et al trials looked at premature birth as a 
potential complication of pregnancy, and addressed other effects of metformin in pregnancy. 
Regardless of the initial trial goal, the final results of all the studies included in this review point to a 
favorable outcome, as metformin appears to have decreased the incidence of both early pregnancy loss 
and premature birth in the participants, as long as compliance with treatment was a factor. However, the 
largest of the three trials, Vanky et al (2010), does not conclude that there is a worthy “benefit of the 
drug on study endpoints, and speaks against this practice.”5 The supposed benefit of metformin here 
was only evident in the fewer number of preterm births after the subgroup analysis was performed, 
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with absolutely no statistically significant difference in either the primary endpoints analysis or the 
subgroup analysis of other pregnancy complications.5  The authors therefore attributed the supposed 
benefit to a “tight and thorough pregnancy follow-up and...diet and lifestyle intervention.”5  The smaller 
trials did attribute the reduction in preterm births and miscarriage to metformin, however, the sample 
size was cited as not adequately large enough to conclude the definitive benefit. Worthy of mention is 
the finding that metformin treatment appears to be safe in pregnant women with PCOS among all three 
trials.5,6,7     
 There are limitations to this study which lead to a potential doubt about the certainty of 
metformin as playing a definitive role in prevention of early pregnancy loss. One limitation is that all 
participants in the trials received comprehensive counseling and health care throughout the duration of 
the trial. This comprehensive health care and follow-up is not necessarily provided to all women 
receiving prenatal care outside the scope of the trials, and may have contributed to a better outcome of 
the pregnancy. Additionally the results may have been skewed by a either a more intense disease course 
or a milder one of study participants, as compared to other women with PCOS. Yet another factor 
consider is pre-pregnancy therapy with metformin, and the different times and gestational ages at 
which metformin therapy was initiated.       
CONCLUSIONS 
 
 Among the data presented in the three trials used for this review metformin appears to be 
effective in reducing early pregnancy loss in women with PCOS. However there are inconsistencies 
present in data interpretations within these trials, which calls for more investigation to be performed. 
Benefits of metformin have been proven in non-pregnant patients with PCOS, and metformin does 
appear to be safe in pregnancy, which has facilitated its use during pregnancy regardless of its 
inconsistent pattern of benefits. Perhaps an entirely separate recommendation could be made to 
increase the quality of prenatal care among women with PCOS, as this was cited as a possible hidden 
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“benefit” of metformin. Future studies should be performed to additionally evaluate the benefit of 
metformin in preventing pregnancy loss or premature delivery, and should further refine the study 
population by including women who have a similar pre-pregnancy history with metformin 
administration, and in whom metformin is initiated preconception and continued through the diagnosis 
of pregnancy. Compliance with treatment should be strongly encouraged to maximize the consistency 
of data results.   
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